Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine Committee on Equitable Allocation of Vaccine for the Novel Coronavirus DISCLAIMER: This discussion draft is not intended to be the final framework recommended by the committee, and the information contained herein is subject to change based on public comments and further committee deliberations. The committeeâs final report and recommended framework is forthcoming. The public comment period will be available from 12:00 p.m. ET on Tuesday, September 1, 2020, until 11:59 p.m. ET on Friday, September 4, 2020. For additional information on how to submit comments, please visit https://www.nationalacademies.org/VaccineAllocationComment Copyright 2020 by the National Academy of Sciences. All rights reserved. DISCUSSION DRAFT FOR PUBLIC COMMENT
BACKGROUND As part of the overall study, the Committee on Equitable Allocation of Vaccine for the Novel Coronavirus is releasing a discussion draft of its framework for public comment. This discussion draft outlines a preliminary framework for equitable allocation of COVID-19 vaccine. Please note that this is a discussion draft of only the framework. Other aspects of the Statement of Task, including risk communication, steps to mitigate vaccine hesitancy, and global considerations will be addressed in the final report. STATEMENT OF TASK An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will develop an overarching framework for vaccine allocation to assist policy makers in the domestic and global health communities in planning for equitable allocation of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The expectation is that such a framework would inform the decisions by health authorities, including the Advisory Committee on Immunization Practices (ACIP), as they create and implement national and/or local guidelines for SARS-CoV-2 vaccine allocation. As part of this effort, the committee will consider the following: â¢ What criteria should be used in setting priorities for equitable allocation of vaccine? â¢ How should the criteria be applied in determining the first tier of vaccine recipients? As more vaccine becomes available, what populations should be added successively to the priority list of recipients? How do we take into account factors such as: o Health disparities and other health access issues o Individuals at higher risk (e.g., elderly, underlying health conditions) o Occupations at higher risk (e.g., health care workers, essential industries, meat packing plants, military) o Populations at higher risk (e.g., racial and ethnic groups, incarcerated individuals, residents of nursing homes, individuals who are homeless) o Geographic distribution of active virus spread o Countries/populations involved in clinical trials â¢ How will the framework apply in various scenarios (e.g., different characteristics of vaccines and differing available doses)? â¢ If multiple vaccine candidates are available, how should we ensure equity? â¢ How can countries ensure equity in allocation of COVID-19 vaccines? â¢ For the United States, how can communities of color be assured access to vaccination? â¢ How can we communicate to the American public about vaccine allocation to minimize perceptions of lack of equity? â¢ What steps should be taken to mitigate vaccine hesitancy, especially among high- priority populations? COMMITTEE SPONSORS Centers for Disease Control and Prevention and National Institutes of Health and DISCUSSION DRAFT FOR PUBLIC COMMENT 2